Durvalumab With or Without Tremelimumab in Metastatic Castration Resistant Prostate Cancer

Summary

The purpose of this study is to find out the effects of giving durvalumab alone or in combination with tremelimumab on this type of cancer. In addition, this study will look at the side effects of durvalumab when given alone or in combination with tremelimumab.

Timeline

Start

2016-12-15

Primary completion

2021-11-22

Completion

2025-05-01

Publications

• Results Winquist E, Hotte SJ, Chi K, Sridhar S, Ellard S, Ong M, Iqbal N, Salim M, Emmenegger U, Gingerich JR, Lalani AK, Major P, Kollmannsberger C, Yip S, Hansen A, Finch D, Canil C, Hutchenreuther J, Vera-Badillo F, Smoragiewicz M, Cabanero M, Tsao MS, Ritch E, Wyatt AW, Seymour L. Randomized Phase II Study of Durvalumab with or without Tremelimumab in Patients with Metastatic Castration-Resistant Prostate Cancer. Clin Cancer Res. 2025 Jan 6;31(1):45-55. doi: 10.1158/1078-0432.CCR-24-1612.

Drugs

Indications